<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958126</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-CAL-09-61</org_study_id>
    <nct_id>NCT00958126</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults Aged 18 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for
      eliciting an immune response to H1N1 influenza in healthy adults
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion Rate 21 Days After the First Vaccination</measure>
    <time_frame>21 days after the first vaccination</time_frame>
    <description>Seroconversion rate: the proportion of participants achieving seroconversion in hemagglutination inhibition (HI) antibody titer. Seroconversion is defined as participants with a baseline titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a baseline HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Rate 21 Days After the Second Vaccination</measure>
    <time_frame>21 days after the second vaccination</time_frame>
    <description>Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After the First Vaccination</measure>
    <time_frame>21 days after the first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an HI Antibody Titer of 1:40 or More 21 Days After the Second Vaccination</measure>
    <time_frame>21 days after the second vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Solicited Adverse Events After the First Vaccination</measure>
    <time_frame>During the 7 days after the first vaccination</time_frame>
    <description>Grade 3 solicited adverse event (AE) definitions: Prevented normal daily activities; Size &gt; 100 mm for injection site redness or induration/swelling; Temperature 102.2°F (39.0°C) or more for fevers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Local Adverse Events After the First Vaccination</measure>
    <time_frame>During the 7 days after the first vaccination, and day 7 - day 21 for ongoing AEs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI) and New Onset of Chronic Illness (NOCI)</measure>
    <time_frame>Up to 180 days after the last vaccination</time_frame>
    <description>A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Unsolicited Adverse Events (UAE) After the First or Second Vaccination</measure>
    <time_frame>Day 0 to Day 20 after each vaccination; up to Day 180 after the last vaccination for SAEs, AESI and NOCI</time_frame>
    <description>Unsolicited adverse event (UAE) grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Enough discomfort to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1313</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>CSL425 (7.5 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL425 (15 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL425 (30 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vaccine diluent. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL425</intervention_name>
    <description>CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.</description>
    <arm_group_label>CSL425 (7.5 mcg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL425</intervention_name>
    <description>CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).</description>
    <arm_group_label>CSL425 (15 mcg)</arm_group_label>
    <arm_group_label>CSL425 (30 mcg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vaccine diluent, thimerosal 0.01% (weight/volume).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 and older, inclusive, at the time of providing informed
             consent.

          -  Females of child bearing potential (i.e., ovulating, pre-menopausal, not surgically
             sterile) must be abstinent or be willing to use a medically accepted contraceptive
             regimen for the duration of the study. Females of child bearing potential must return
             a negative urine pregnancy test result at enrolment and prior to each study
             vaccination.

        Exclusion Criteria:

          -  Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to
             eggs, chicken protein, thimerosal, neomycin, polymyxin, or any components of the Study
             Vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Vaccines Clinical Development</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, Rockman S, Jeanfreau RJ, Ghosh MR, Kabongo ML, Gittleson C, Karron RA. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis. 2010 Nov 1;202(9):1327-37. doi: 10.1086/656601.</citation>
    <PMID>20874515</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <results_first_submitted>July 5, 2012</results_first_submitted>
  <results_first_submitted_qc>August 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2012</results_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Adults</title>
          <description>Vaccine diluent; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="P2">
          <title>CSL425 (7.5 mcg), Adults</title>
          <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="P3">
          <title>CSL425 (15 Mcg), Adults</title>
          <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="P4">
          <title>CSL425 (30 Mcg), Adults</title>
          <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="P5">
          <title>Placebo, Older Adults</title>
          <description>Vaccine diluent; Older adults aged 65 years or older</description>
        </group>
        <group group_id="P6">
          <title>CSL425 (7.5 Mcg), Older Adults</title>
          <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
        </group>
        <group group_id="P7">
          <title>CSL425 (15 Mcg), Older Adults</title>
          <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
        </group>
        <group group_id="P8">
          <title>CSL425 (30 Mcg), Older Adults</title>
          <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="201"/>
                <participants group_id="P4" count="203"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="203"/>
                <participants group_id="P7" count="200"/>
                <participants group_id="P8" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="191"/>
                <participants group_id="P4" count="192"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="202"/>
                <participants group_id="P7" count="199"/>
                <participants group_id="P8" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved away from study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor/Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo, Adults</title>
          <description>Vaccine diluent; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="B2">
          <title>CSL425 (7.5 mcg), Adults</title>
          <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="B3">
          <title>CSL425 (15 Mcg), Adults</title>
          <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="B4">
          <title>CSL425 (30 Mcg), Adults</title>
          <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="B5">
          <title>Placebo, Older Adults</title>
          <description>Vaccine diluent; Older adults aged 65 years or older</description>
        </group>
        <group group_id="B6">
          <title>CSL425 (7.5 Mcg), Older Adults</title>
          <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
        </group>
        <group group_id="B7">
          <title>CSL425 (15 Mcg), Older Adults</title>
          <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
        </group>
        <group group_id="B8">
          <title>CSL425 (30 Mcg), Older Adults</title>
          <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="205"/>
            <count group_id="B3" value="201"/>
            <count group_id="B4" value="203"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="203"/>
            <count group_id="B7" value="200"/>
            <count group_id="B8" value="202"/>
            <count group_id="B9" value="1313"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= 18 years to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="203"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="203"/>
                    <measurement group_id="B7" value="200"/>
                    <measurement group_id="B8" value="202"/>
                    <measurement group_id="B9" value="655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="120"/>
                    <measurement group_id="B7" value="108"/>
                    <measurement group_id="B8" value="112"/>
                    <measurement group_id="B9" value="749"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="83"/>
                    <measurement group_id="B7" value="92"/>
                    <measurement group_id="B8" value="90"/>
                    <measurement group_id="B9" value="564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate 21 Days After the First Vaccination</title>
        <description>Seroconversion rate: the proportion of participants achieving seroconversion in hemagglutination inhibition (HI) antibody titer. Seroconversion is defined as participants with a baseline titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a baseline HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
        <time_frame>21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Adults</title>
            <description>Vaccine diluent; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg), Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 Mcg), Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 Mcg), Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O5">
            <title>Placebo, Older Adults</title>
            <description>Vaccine diluent; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (7.5 Mcg), Older Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O7">
            <title>CSL425 (15 Mcg), Older Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O8">
            <title>CSL425 (30 Mcg), Older Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate 21 Days After the First Vaccination</title>
          <description>Seroconversion rate: the proportion of participants achieving seroconversion in hemagglutination inhibition (HI) antibody titer. Seroconversion is defined as participants with a baseline titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a baseline HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
          <population>The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="195"/>
                <count group_id="O4" value="199"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="201"/>
                <count group_id="O7" value="197"/>
                <count group_id="O8" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O2" value="82" lower_limit="76.0" upper_limit="87.1"/>
                    <measurement group_id="O3" value="88.2" lower_limit="82.8" upper_limit="92.4"/>
                    <measurement group_id="O4" value="94.5" lower_limit="90.3" upper_limit="97.2"/>
                    <measurement group_id="O5" value="2.1" lower_limit="0.1" upper_limit="11.1"/>
                    <measurement group_id="O6" value="51.2" lower_limit="44.1" upper_limit="58.3"/>
                    <measurement group_id="O7" value="58.9" lower_limit="51.7" upper_limit="65.8"/>
                    <measurement group_id="O8" value="73.0" lower_limit="66.3" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Solicited Adverse Events After the First Vaccination</title>
        <description>Grade 3 solicited adverse event (AE) definitions: Prevented normal daily activities; Size &gt; 100 mm for injection site redness or induration/swelling; Temperature 102.2°F (39.0°C) or more for fevers.</description>
        <time_frame>During the 7 days after the first vaccination</time_frame>
        <population>The Safety Population (first vaccination) comprised all randomized participants who received the first vaccination and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Adults</title>
            <description>Vaccine diluent; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg), Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 Mcg), Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 Mcg), Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O5">
            <title>Placebo, Older Adults</title>
            <description>Vaccine diluent; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (7.5 Mcg), Older Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O7">
            <title>CSL425 (15 Mcg), Older Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O8">
            <title>CSL425 (30 Mcg), Older Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Solicited Adverse Events After the First Vaccination</title>
          <description>Grade 3 solicited adverse event (AE) definitions: Prevented normal daily activities; Size &gt; 100 mm for injection site redness or induration/swelling; Temperature 102.2°F (39.0°C) or more for fevers.</description>
          <population>The Safety Population (first vaccination) comprised all randomized participants who received the first vaccination and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="203"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="203"/>
                <count group_id="O7" value="200"/>
                <count group_id="O8" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="11.8" upper_limit="36.6"/>
                    <measurement group_id="O2" value="28.9" lower_limit="22.8" upper_limit="35.7"/>
                    <measurement group_id="O3" value="35.8" lower_limit="29.2" upper_limit="42.9"/>
                    <measurement group_id="O4" value="52.7" lower_limit="45.6" upper_limit="59.7"/>
                    <measurement group_id="O5" value="4.0"/>
                    <measurement group_id="O6" value="13.3"/>
                    <measurement group_id="O7" value="23.5"/>
                    <measurement group_id="O8" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="5.9" upper_limit="27.2"/>
                    <measurement group_id="O2" value="14.7" lower_limit="10.1" upper_limit="20.3"/>
                    <measurement group_id="O3" value="17.4" lower_limit="12.4" upper_limit="23.4"/>
                    <measurement group_id="O4" value="31.0" lower_limit="24.7" upper_limit="37.9"/>
                    <measurement group_id="O5" value="2.0"/>
                    <measurement group_id="O6" value="2.0"/>
                    <measurement group_id="O7" value="4.0"/>
                    <measurement group_id="O8" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="1.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0.5"/>
                    <measurement group_id="O7" value="1.0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="3.9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2.0"/>
                    <measurement group_id="O7" value="3.0"/>
                    <measurement group_id="O8" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="32.8"/>
                    <measurement group_id="O4" value="46.8"/>
                    <measurement group_id="O5" value="4.0"/>
                    <measurement group_id="O6" value="10.3"/>
                    <measurement group_id="O7" value="20.0"/>
                    <measurement group_id="O8" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bruising at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.4"/>
                    <measurement group_id="O3" value="4.0"/>
                    <measurement group_id="O4" value="1.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.5"/>
                    <measurement group_id="O7" value="3.0"/>
                    <measurement group_id="O8" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 bruising at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any solicited systemic adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="35.3"/>
                    <measurement group_id="O3" value="34.8"/>
                    <measurement group_id="O4" value="40.9"/>
                    <measurement group_id="O5" value="18.0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="24.0"/>
                    <measurement group_id="O8" value="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="21.4"/>
                    <measurement group_id="O4" value="27.1"/>
                    <measurement group_id="O5" value="8.0"/>
                    <measurement group_id="O6" value="9.4"/>
                    <measurement group_id="O7" value="10.5"/>
                    <measurement group_id="O8" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0.5"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="16.4"/>
                    <measurement group_id="O4" value="17.2"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="5.4"/>
                    <measurement group_id="O7" value="9.5"/>
                    <measurement group_id="O8" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="15.9"/>
                    <measurement group_id="O4" value="17.7"/>
                    <measurement group_id="O5" value="8.0"/>
                    <measurement group_id="O6" value="8.9"/>
                    <measurement group_id="O7" value="13.0"/>
                    <measurement group_id="O8" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="8.0"/>
                    <measurement group_id="O4" value="7.9"/>
                    <measurement group_id="O5" value="2.0"/>
                    <measurement group_id="O6" value="1.0"/>
                    <measurement group_id="O7" value="2.5"/>
                    <measurement group_id="O8" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="5.4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0.5"/>
                    <measurement group_id="O7" value="1.0"/>
                    <measurement group_id="O8" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="1.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0.5"/>
                    <measurement group_id="O8" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="3.0"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0.5"/>
                    <measurement group_id="O8" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Local Adverse Events After the First Vaccination</title>
        <time_frame>During the 7 days after the first vaccination, and day 7 - day 21 for ongoing AEs</time_frame>
        <population>The Safety Population (first vaccination) comprised all randomized participants who received the first vaccination and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Adults</title>
            <description>Vaccine diluent; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg), Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 Mcg), Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 Mcg), Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O5">
            <title>Placebo, Older Adults</title>
            <description>Vaccine diluent; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (7.5 Mcg), Older Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O7">
            <title>CSL425 (15 Mcg), Older Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O8">
            <title>CSL425 (30 Mcg), Older Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local Adverse Events After the First Vaccination</title>
          <population>The Safety Population (first vaccination) comprised all randomized participants who received the first vaccination and provided follow-up safety data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="203"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="203"/>
                <count group_id="O7" value="200"/>
                <count group_id="O8" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.378"/>
                    <measurement group_id="O2" value="1.87" spread="2.705"/>
                    <measurement group_id="O3" value="1.71" spread="0.926"/>
                    <measurement group_id="O4" value="1.91" spread="1.237"/>
                    <measurement group_id="O5" value="1.00">n = 1</measurement>
                    <measurement group_id="O6" value="1.75" spread="0.957"/>
                    <measurement group_id="O7" value="1.75" spread="0.886"/>
                    <measurement group_id="O8" value="1.27" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">n = 0</measurement>
                    <measurement group_id="O2" value="1.00" spread="0.000"/>
                    <measurement group_id="O3" value="1.00">n = 1</measurement>
                    <measurement group_id="O4" value="2.50" spread="0.707"/>
                    <measurement group_id="O5" value="NA">n = 0</measurement>
                    <measurement group_id="O6" value="1.00">n = 1</measurement>
                    <measurement group_id="O7" value="1.00" spread="0.000"/>
                    <measurement group_id="O8" value="NA">n = 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">n = 0</measurement>
                    <measurement group_id="O2" value="1.56" spread="0.726"/>
                    <measurement group_id="O3" value="1.2" spread="0.447"/>
                    <measurement group_id="O4" value="3.38" spread="2.615"/>
                    <measurement group_id="O5" value="NA">n = 0</measurement>
                    <measurement group_id="O6" value="6.00" spread="10.00"/>
                    <measurement group_id="O7" value="1.5" spread="0.837"/>
                    <measurement group_id="O8" value="3.2" spread="4.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.912"/>
                    <measurement group_id="O2" value="2.04" spread="2.813"/>
                    <measurement group_id="O3" value="1.85" spread="0.966"/>
                    <measurement group_id="O4" value="1.90" spread="1.082"/>
                    <measurement group_id="O5" value="1.5" spread="0.707"/>
                    <measurement group_id="O6" value="1.27" spread="0.550"/>
                    <measurement group_id="O7" value="1.71" spread="0.955"/>
                    <measurement group_id="O8" value="1.65" spread="1.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">n = 0</measurement>
                    <measurement group_id="O2" value="3.00" spread="2.539"/>
                    <measurement group_id="O3" value="2.25" spread="1.669"/>
                    <measurement group_id="O4" value="2.00" spread="0.000"/>
                    <measurement group_id="O5" value="NA">n = 0</measurement>
                    <measurement group_id="O6" value="8.00" spread="11.269"/>
                    <measurement group_id="O7" value="4.33" spread="2.503"/>
                    <measurement group_id="O8" value="1.20" spread="0.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate 21 Days After the Second Vaccination</title>
        <description>Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
        <time_frame>21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Adults</title>
            <description>Vaccine diluent; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg), Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 Mcg), Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 Mcg), Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O5">
            <title>Placebo, Older Adults</title>
            <description>Vaccine diluent; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (7.5 Mcg), Older Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O7">
            <title>CSL425 (15 Mcg), Older Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O8">
            <title>CSL425 (30 Mcg), Older Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate 21 Days After the Second Vaccination</title>
          <description>Seroconversion rate: the percentage of participants achieving seroconversion in HI antibody titer. Seroconversion is defined as participants with a pre-vaccination titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a pre-vaccination HI titer of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titer.</description>
          <population>The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccine; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="191"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="196"/>
                <count group_id="O8" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="1.3" upper_limit="17.2"/>
                    <measurement group_id="O2" value="83.2" lower_limit="77.2" upper_limit="88.1"/>
                    <measurement group_id="O3" value="91.1" lower_limit="86.1" upper_limit="94.7"/>
                    <measurement group_id="O4" value="95.9" lower_limit="92.0" upper_limit="98.2"/>
                    <measurement group_id="O5" value="8.3" lower_limit="2.3" upper_limit="20.0"/>
                    <measurement group_id="O6" value="59.5" lower_limit="52.3" upper_limit="66.4"/>
                    <measurement group_id="O7" value="67.3" lower_limit="60.3" upper_limit="73.9"/>
                    <measurement group_id="O8" value="75.3" lower_limit="68.6" upper_limit="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After the First Vaccination</title>
        <time_frame>21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Adults</title>
            <description>Vaccine diluent; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg), Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 Mcg), Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 Mcg), Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O5">
            <title>Placebo, Older Adults</title>
            <description>Vaccine diluent; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (7.5 Mcg), Older Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O7">
            <title>CSL425 (15 Mcg), Older Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O8">
            <title>CSL425 (30 Mcg), Older Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an Hemagglutination Inhibition (HI) Antibody Titer of 1:40 or More 21 Days After the First Vaccination</title>
          <population>The Evaluable Population (for the first vaccination) comprised all randomized participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="195"/>
                <count group_id="O4" value="199"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="201"/>
                <count group_id="O7" value="197"/>
                <count group_id="O8" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="12.0" upper_limit="37.3"/>
                    <measurement group_id="O2" value="97.0" lower_limit="93.6" upper_limit="98.9"/>
                    <measurement group_id="O3" value="96.4" lower_limit="92.7" upper_limit="98.5"/>
                    <measurement group_id="O4" value="99.5" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="39.6" lower_limit="25.8" upper_limit="54.7"/>
                    <measurement group_id="O6" value="92.0" lower_limit="87.4" upper_limit="95.4"/>
                    <measurement group_id="O7" value="90.9" lower_limit="85.9" upper_limit="94.5"/>
                    <measurement group_id="O8" value="94.0" lower_limit="89.8" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an HI Antibody Titer of 1:40 or More 21 Days After the Second Vaccination</title>
        <time_frame>21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Adults</title>
            <description>Vaccine diluent; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg), Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 Mcg), Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 Mcg), Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O5">
            <title>Placebo, Older Adults</title>
            <description>Vaccine diluent; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (7.5 Mcg), Older Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O7">
            <title>CSL425 (15 Mcg), Older Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O8">
            <title>CSL425 (30 Mcg), Older Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an HI Antibody Titer of 1:40 or More 21 Days After the Second Vaccination</title>
          <population>The Evaluable Population (for the second vaccination) comprised all randomized participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="191"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="200"/>
                <count group_id="O7" value="196"/>
                <count group_id="O8" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="17.0" upper_limit="44.1"/>
                    <measurement group_id="O2" value="98.5" lower_limit="95.6" upper_limit="99.7"/>
                    <measurement group_id="O3" value="99.5" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="99.5" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O5" value="35.4" lower_limit="22.2" upper_limit="50.5"/>
                    <measurement group_id="O6" value="96.0" lower_limit="92.3" upper_limit="98.3"/>
                    <measurement group_id="O7" value="93.4" lower_limit="88.9" upper_limit="96.4"/>
                    <measurement group_id="O8" value="94.9" lower_limit="90.9" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI) and New Onset of Chronic Illness (NOCI)</title>
        <description>A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).</description>
        <time_frame>Up to 180 days after the last vaccination</time_frame>
        <population>The Safety Population comprised all randomized participants who received at least one dose of study vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Adults</title>
            <description>Vaccine diluent; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg), Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 Mcg), Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 Mcg), Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
          </group>
          <group group_id="O5">
            <title>Placebo, Older Adults</title>
            <description>Vaccine diluent; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O6">
            <title>CSL425 (7.5 Mcg), Older Adults</title>
            <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O7">
            <title>CSL425 (15 Mcg), Older Adults</title>
            <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
          <group group_id="O8">
            <title>CSL425 (30 Mcg), Older Adults</title>
            <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI) and New Onset of Chronic Illness (NOCI)</title>
          <description>A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).</description>
          <population>The Safety Population comprised all randomized participants who received at least one dose of study vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="203"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="203"/>
                <count group_id="O7" value="200"/>
                <count group_id="O8" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of participants with at least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="2.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="6.0"/>
                    <measurement group_id="O6" value="4.4"/>
                    <measurement group_id="O7" value="3.0"/>
                    <measurement group_id="O8" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants with related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants with at least one AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants with related AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants with at least one NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="2.0"/>
                    <measurement group_id="O6" value="1.0"/>
                    <measurement group_id="O7" value="2.5"/>
                    <measurement group_id="O8" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants with related NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Unsolicited Adverse Events (UAE) After the First or Second Vaccination</title>
        <description>Unsolicited adverse event (UAE) grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Enough discomfort to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.</description>
        <time_frame>Day 0 to Day 20 after each vaccination; up to Day 180 after the last vaccination for SAEs, AESI and NOCI</time_frame>
        <population>The Safety Population comprised all randomized participants who received at least one dose of study vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Age Cohorts Combined</title>
            <description>Vaccine diluent</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (7.5 mcg), Age Cohorts Combined</title>
            <description>7.5 mcg of hemagglutinin antigen per dose</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (15 Mcg), Age Cohorts Combined</title>
            <description>15 mcg of hemagglutinin antigen per dose</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 Mcg), Age Cohorts Combined</title>
            <description>30 mcg of hemagglutinin antigen per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Unsolicited Adverse Events (UAE) After the First or Second Vaccination</title>
          <description>Unsolicited adverse event (UAE) grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Enough discomfort to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.</description>
          <population>The Safety Population comprised all randomized participants who received at least one dose of study vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="407"/>
                <count group_id="O3" value="401"/>
                <count group_id="O4" value="405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of participants with at least one UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="27.5"/>
                    <measurement group_id="O3" value="30.2"/>
                    <measurement group_id="O4" value="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants reporting Grade 1 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="12.8"/>
                    <measurement group_id="O3" value="10.0"/>
                    <measurement group_id="O4" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants reporting Grade 2 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="14.0"/>
                    <measurement group_id="O4" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants reporting Grade 3 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="6.2"/>
                    <measurement group_id="O4" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For SAEs: up to 180 days after the last vaccination. For unsolicited adverse events: 21 days after the first study vaccination, up to 180 days after the the last vaccination (for AESI and NOCI).</time_frame>
      <desc>Serious Adverse Events were collected from Day 0 to 180 days after the last vaccination.
The other adverse events presented are unsolicited adverse events from Day 0 to Day 20 days after the first study vaccination, AESI and NOCI from Day 0 to 180 days after the last vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo, Adults</title>
          <description>Vaccine diluent; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="E2">
          <title>CSL425 (7.5 mcg), Adults</title>
          <description>7.5 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="E3">
          <title>CSL425 (15 Mcg), Adults</title>
          <description>15 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="E4">
          <title>CSL425 (30 Mcg), Adults</title>
          <description>30 mcg of hemagglutinin antigen per dose; Adults aged 18 to 64 years</description>
        </group>
        <group group_id="E5">
          <title>Placebo, Older Adults</title>
          <description>Vaccine diluent; Older adults aged 65 years or older</description>
        </group>
        <group group_id="E6">
          <title>CSL425 (7.5 Mcg), Older Adults</title>
          <description>7.5 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
        </group>
        <group group_id="E7">
          <title>CSL425 (15 Mcg), Older Adults</title>
          <description>15 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
        </group>
        <group group_id="E8">
          <title>CSL425 (30 Mcg), Older Adults</title>
          <description>30 mcg of hemagglutinin antigen per dose; Older adults aged 65 years or older</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Fibrous dysplasia of bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Viral myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lung metastatic cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="203"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="203"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="200"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="203"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

